<DOC>
	<DOCNO>NCT02526979</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) mirabegron oral suspension single dose administration child neurogenic detrusor overactivity ( NDO ) overactive bladder ( OAB ) . This study also evaluate safety tolerability well acceptability palatability mirabegron oral suspension single dose administration child NDO OAB .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability Mirabegron Oral Suspension Pediatric Subjects From 3 Less Than 12 Years Age With Neurogenic Detrusor Overactivity ( NDO ) Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject male female 3 less 12 year age . Subject document diagnosis accord International Children 's Continence Society ( ICCS ) criterion : NDO , Idiopathic OAB Subject 's weight/height : Subject must body weight ≥ 15.0 kg For NDO : subject suffer malnutrition grossly overweight , opinion Investigator For OAB : subject 's weight height within normal percentile ( 3rd 97th percentile ) accord Centers Disease Control Prevention ( CDC ) growth chart . Subject able swallow study medication accordance protocol . Subject subject 's parent ( ) /legal guardian agree subject participate another interventional study treatment . Subject subject 's parent ( ) /legal guardian willing able comply study requirement concomitant medication restriction . Female subject must : Be nonchildbearing potential : Clearly premenarchal judgment Investigator premenarchal . Or follow inclusion criterion follow , applicable ( rare case ) : Female subject reach puberty must : Agree try become pregnant study 28 day final study drug administration , And negative urine pregnancy test predose Day 1 , And , heterosexually active agree consistently use 2 form highly effective form birth control start screen throughout study period for28 day final study drug administration . Subject known history QTc prolongation risk QT prolongation ( e.g . hypokalemia , family history Long QT Syndrome ) and/or QTcB &gt; 460 ms. Subject ( mean ) rest pulse rate &gt; 99th percentile [ Fleming et al , 2011 ] . Subject clinically significant ECG ( electrocardiogram ) abnormality . Subject establish hypertension systolic diastolic blood pressure great 99th percentile normal range determine sex , age height , plus 5mmHg [ NIH 2005 ] . Subject clinically significant unstable medical condition disorder , opinion Investigator , preclude subject participate study . Subject current , untreated constipation ( fecal impaction NDO subject ) . If constipation consistently treat last month , subject include . Subject administer intradetrusor botulinum toxin injection ; except give &gt; 4 month prior screen symptom reappear comparable botulinum toxin injection . Subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great equal 2 time ULN total bilirubin great equal 1.5 time ULN . Subject severe renal impairment ( estimate glomerular filtration rate &lt; 30 mL/min ( Larsson ) ) . Subject clinically significant range result urinalysis , biochemistry hematology . Subject history current diagnosis malignancy . Subject know suspected hypersensitivity mirabegron , ß3agonists , excipients use mirabegron oral suspension formulation previous severe hypersensitivity drug . Subject meet contra indication precaution use mirabegron list Investigator 's Brochure ( IB ) . Subject use mirabegron within 12 day plan Reference Day ( Day 4 Day 1 ) . Subject require ongoing treatment follow prohibited medication : Any anticholinergic/antimuscarinic drug within 5 halflives prior plan Reference Day ( Day 4 Day 1 ) . Any drug sensitive CYP2D6 substrates narrow therapeutic index ( thioridazine , flecainide , propafenone , imipramine , desipramine ) sensitive Pgp substrate ( digoxin , dabigatran ) within 5 halflives prior plan Reference Day ( Day 4 Day 1 ) . Any moderate strong cytochrome CYP3A4/5 Pgp inhibitor inducer include natural herbal remedy ( itraconazole , rifampicin , phenytoin , carbamazepine , St. John 's Wort , grapefruit , Seville orange ) within 4 week ( inducer ) 5 halflives ( inhibitor ) prior plan Reference Day ( Day 4 Day 1 ) . Subject participate another clinical trial and/or take investigational drug within 30 day ( 5 halflives investigational drug , whichever long ) prior plan Reference Day ( Day 4 Day 1 ) . Subject 's parent ( ) /legal guardian employee Astellas Group , Contract Research Organization ( CRO ) involve , Investigator site execute study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>OAB</keyword>
	<keyword>overactive bladder</keyword>
	<keyword>Myrbetric</keyword>
	<keyword>neurogenic detrusor overactivity</keyword>
	<keyword>Betanis</keyword>
	<keyword>Myrbetriq</keyword>
	<keyword>NDO</keyword>
	<keyword>YM178</keyword>
	<keyword>mirabegron</keyword>
	<keyword>Betmiga</keyword>
</DOC>